Clinical Trials Logo
  1. Home
  2. Raynaud Disease
  3. NCT00934427

Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms

Raynaud Disease Clinical Trial

Official title:
A Study of a Topical Formulation of Nitroglycerin, Vascana® (MQX-503), and Matching Vehicle in the Treatment and Prevention of Symptoms Associated With Raynaud's Phenomenon

Clinical Trial Summary

The purpose of this study is to determine if Vascana, a novel topical formulation of nitroglycerin, is effective in the treatment and prevention of the symptoms associated with Raynaud's Phenomenon.

Clinical Trial Description

Raynaud's Phenomenon is a sometimes debilitating condition in which blood flow to the fingers or toes is compromised when a patient is exposed to cold or stress. Current therapies for Raynaud's are suboptimal because they are associated with significant side effects. In this study, patient responses to cold temperature exposures in a climate-controlled room after application of the study medication are measured. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00934427
Study type Interventional
Source MediQuest Therapeutics
Contact
Status Active, not recruiting
Phase Phase 3
Start date June 2009
Completion date July 2010
View Details
See also
  Status Clinical Trial Phase
Completed NCT01926847 - Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator Phase 2
Completed NCT03699436 - Effectiveness of Electric Stimulation Therapy in Raynaud's Phenomenon N/A
Terminated NCT02374320 - Exparel as a Nerve Block for Severe Hand Pain Phase 2/Phase 3
Completed NCT00251238 - Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon Phase 2
Completed NCT00253331 - Lab Study of MQX-503 in Treatment of Raynaud's Phase 2/Phase 3
Recruiting NCT02183779 - PORH and Response to Cold in Raynaud's Phenomenon. N/A
Completed NCT02506062 - A Trial of Ischemic Preconditioning in Raynaud's Phenomenon (RP) N/A
Terminated NCT02642146 - Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: a Prospective Cohort Study
Completed NCT01743612 - Laser Speckle Contrast Imaging for Cutaneous Microvascular Dysfunction Detection in Systemic Sclerosis. N/A
Completed NCT03094910 - Investigation of the Rewarming og the Fingers After Cooling and the Autonomic Nervous System in Raynaud's Phenomenon N/A
Recruiting NCT02298777 - Metabolomic Analysis of Systemic Sclerosis
Completed NCT00626665 - Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Phase 3
Completed NCT00004786 - Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis Phase 3
Withdrawn NCT04898036 - Phototherapy For Treatment Of Raynaud's Phenomenon N/A
Completed NCT03027674 - Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud N/A
Terminated NCT03869008 - Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena. N/A